Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Choosing Alzheimer's disease prevention clinical trial populations.

Neurobiology of aging - 1 Mar 2014

Grill Joshua D, Monsell Sarah E

Abstract excerpt

To assist investigators in making design choices, we modeled Alzheimer's disease prevention clinical trials. We used longitudinal Clinical Dementia Rating Scale Sum of Boxes data, retention rates, and the proportions of trial-eligible cognitively normal participants age 65 and older in the National Alzheimer's Coordinating Center Uniform Data Set to model trial sample sizes, the numbers needed to enroll to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials as Topic
Share to Cognition
Share to Cognitive Dysfunction

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Education

Share to Interview, Psychological

Share to Memory

Share to Patient Selection

Share to Sample Size

Source

Open in PubMed Open full text

Identifiers

PMID: 24119546
DOI: 10.1016/j.neurobiolaging.2013.09.001
PMCID: PMC3864603

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Choosing Alzheimer's disease prevention clinical trial populations.PMID 24119546Read ↗

Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging InitiativeSemantic proximity Read ↗

Effect of <i>APOE</i> genotype status on targeted clinical trials outcomes and efficiency in dementia and mild cognitive impairment resulting from Alzheimer's diseaseSemantic proximity Read ↗

Generalizability of trial criteria on amyloid-lowering therapy against Alzheimer’s disease to individuals with MCI or early AD in the general populationSemantic proximity Read ↗

Clinical trials in predementia stages of Alzheimer disease.Semantic proximity Read ↗

Use of preclinical Alzheimer’s disease trajectories for clinical trial designSemantic proximity Read ↗

Using Real-World Data to Rationalize Clinical Trials Eligibility Criteria Design: A Case Study of Alzheimer’s Disease TrialsSemantic proximity Read ↗

A Machine Learning Approach to Predict Cognitive Decline in Alzheimer’s Disease Clinical TrialsSemantic proximity Read ↗

Racial and Ethnic Reporting and Representation in Phase III Alzheimer’s Disease Clinical Trials in the USSemantic proximity Read ↗

Design-Induced Circularity in Alzheimer’s Biomarker Trials and Trial-Ready Cohorts: Enrichment, Data-Driven Selection, and Estimand MismatchSemantic proximity Read ↗

Using Historical Data to Facilitate Clinical Prevention Trials in Alzheimer Disease?Semantic proximity Read ↗

Development of Novel Measures for Alzheimer’s Disease Prevention Trials (NoMAD)Semantic proximity Read ↗

Reducing placebo response in clinical trials of agitation in Alzheimer’s diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.